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http://www.gutpathogens.com/content/5/1/34SHORT REPORT Open AccessESBL-plasmids carrying toxin-antitoxin systems
can be “cured” of wild-type Escherichia coli using
a heat technique
Katharina Schaufler1*, Lothar H Wieler1, Torsten Semmler1, Christa Ewers2 and Sebastian Guenther1Abstract
Background: Plasmid-encoded extended-spectrum beta-lactamase (ESBL)-enzymes are frequently produced by
Escherichia coli. Several ESBL-plasmids contain genes for toxin-antitoxin (TA) systems, which assure the maintenance
of plasmids in bacteria and prevent the cells from “post-segregational killing”. These systems limit options to “cure”
plasmids of ESBL-wild-type strains due to the death of the bacterial cells. A helpful tool to understand the role of
ESBL-plasmids in the dissemination of pandemic multi-resistant E. coli are ESBL-plasmid-“cured”-variants (PCVs) and
their comparison to ESBL-wild-type strains. The purpose of this study was to construct PCVs of ESBL-wild-type E. coli
strains despite the presence of genes for TA systems.
Findings: Using enhanced temperatures and brain-heart-infusion broth it was possible to construct viable PCVs of
wild-type ESBL-E. coli strains. The occurrence of TA system-genes including hok/sok, srnB/C, vagC/D, pemI/K on
ESBL-plasmids of replicon types FIA or FIB was demonstrated by bioinformatic analyses. The loss of the plasmid and
the genetic identity of PCV and corresponding wild-type strain was confirmed via different methods including
plasmid-profile-analysis, pulsed-field gel electrophoresis and bioinformatics using generated whole genome data of
the strains.
Conclusions: This short report describes the successful construction of viable PCVs of ESBL-wild-type E. coli strains.
The results are hence surprising due to the fact that all “cured” ESBL-plasmids contained at least one complete
toxin-antitoxin system, whose loss would normally mean the death of bacterial cells.
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Pathogenic Escherichia coli cause a wide range of infectious
diseases in various animal species and humans, including
diarrhoea [1], meningitis, urinary tract and, soft tissue
infections [2]. Many E. coli produce extended-spectrum
beta-lactamase (ESBL)-enzymes, which- in addition to
penicillins and others- hydrolyse newer, third-generation
cephalosporins and monobactams [3], and limit antimicro-
bial therapy. Several ESBL-gene families (blaCTX-M, blaSHV,
blaTEM and blaOXA) are encoded on plasmids [4]. Prior re-
search has demonstrated that some of the ESBL-carrying
plasmids influence factors other than resistance, like the
ability of Klebsiella strains to invade epithelial cells [5]. In* Correspondence: katharina.schaufler@fu-berlin.de
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stated.these ESBL-plasmids, addiction models such as toxin-
antitoxin (TA) systems have been described [6], which
prevent the cell from “post-segregational killing”, therefore
ensuring the maintenance of the plasmid in the bacterial
cell during replication [7]. Several TA systems have been
discovered in Gram-negative and Gram-positive bacteria
differing basically in functionality and type of the antitoxin.
Type I system antitoxins are small antisense RNA mol-
ecules, which mostly inhibit toxin mRNA translation
or degrade toxin mRNA while type II system protein
antitoxins interact post-translationally with protein toxins.
Other systems are type III to type V TA systems [8-10].
One of the first [11] and most studied is type I hok/sok TA
system in E. coli. Following replication, in plasmid-free
daughter cells type I unstable RNA antitoxin molecules
(e.g. sok) degrade rapidly, while stable toxins (e.g. hok)
induce cell membrane porins, therefore impairing ATPal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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FIA/FIB hok/sok blaTEM-1, tet(A), sul2, strA, aac(3)-IV,
aac(6’)-Ib-cr.
IMT27685 Raven (C. corax) Feces 131 CTX-M-15 not typed pemI/pemK,
vagC/D








tet(A), tet(R), sul1, sul2, strA, strB, aadA,
aac(3)-II mph(A), mrx, mphR, dhfrVII,




648 CTX-M-15 FIA/FIB pemI/K, vagC/D,
srnB/C








FIA vagC/D, srnB/C tet(A), tet(R), sul1, sul2, strA, strB, aadA,
aac(3)-II, mph(A), mphR, dhfrVII
IMT23463 Monk vulture
(A. monachus)
Feces 648 CTX-M-9 FIB PemI/pemK,
srnB/C, hok/sok
blaTEM-1, blaOXA-1, tet(A),sul2, strA, strB,
aac(6’)-Ib-cr
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In ESBL-plasmids most frequently represented systems not
only include hok/sok but also pemK/I and ccdA/B, which
seem to be associated with CTX-M-15 and CTX-M-9
encoding plasmids of IncF replicon type [13]. To investi-
gate, which important role ESBL-plasmids play concern-
ing both resistance and factors not related to resistance it
is necessary to construct ESBL-plasmid-“cured”-variants
(PCVs) and compare those pheno- and genotypically to
ESBL-wild-type strains. Different methods are known
to “cure” bacterial plasmids, most of them use chemical
treatment like ethidium bromide or acridine orange in
different concentrations added to bacteria in Luria-Broth
(LB) [14]. These methods often involve the problem that
“curing” the ESBL-plasmid of the wild-type strain causesTable 2 Results of agar disc diffusion testing
Strain designation Cefotaxime Chloramphenicol Enrofloxacin Ge
VB977549 R S R S
PCV977549 S S R S
IMT19205 R S R R
PCV19205 S S S R
IMT27685 R R R S
PCV27685 S S R S
IMT16316 R S R R
PCV16316 S S R S
VB964041.2 R S R R
PCV964041.2 S S R S
IMT21183 R S R R
PCV21183 S S R S
IMT23463 R S R S
PCV23463 S S R S
(R = resistant, S = sensitive, I = intermediate).the death of the bacterium due to the loss of an operating
TA system. In this study we “cured” TA systems-containing
ESBL-plasmids from wild-type E. coli testing an established
method [15] using enhanced temperatures, brain-heart-
infusion (BHI) medium and several weeks of continuing
sub-cultivation protocols.
Material and methods
To force the loss of the ESBL-plasmid, a heat technique
was performed [15]. Single colonies of seven wild-type
ESBL-E. coli strains (VB977549, IMT19205, IMT27685,
IMT16316, VB964041.2, IMT21183, IMT23463 of success-
ful and pandemic sequence types [STs] ST131 and ST648
and different hosts including humans, companion and wild
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microliters of the overnight culture were spread on CHRO-
MagarTM plates. Plates were incubated at 37°C overnight.
Replicate CHROMagarTM plates containing an identicalFigure 1 Dendrograms of the pulsed-field gel electrophoresis. Wild-ty
PFGE (dice similarity value >98% for all strains). Software: Bionumerics (Appnumbered grid on the backside of the plate were then pre-
pared. One contained cefotaxime (4 μg/ml cefotaxime) and
the other was prepared without supplementation of antibi-
otics. Twenty single colonies of each strain were randomlype ESBL-E. coli and PCV strains after macrorestriction with XbaI and
lied Maths, Belgium).
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plate and single colonies were placed on their identical
grid locations in the agar of the replicate plates. This
was to ensure that colonies from the two different plates
could be assigned to the previously selected, single colony.
ESBL-plasmid-“cured” single clones should not grow on
cefotaxime-containing plates. These visually “cured” single
clones were picked from the corresponding CHROMagarTM
plate without cefotaxime according to the grid and their
phenotypic resistance against cefotaxime and other anti-
microbial classes (Table 2) was screened using agar disc
diffusion according to the CLSI method [16]. They were
further investigated using plasmid-profile-analysis to prove
the loss of the plasmid [17]. Clonal identity of the wild-
type and the ESBL-plasmid-“cured”-variant was tested via
XbaI-pulsed-field gel electrophoresis (PFGE) [18] and
following comparative bioinformatic analyses. First, the
number of orthologous genes in a pairwise comparison
of the genome of the wild-type strain and the corresponding
plasmid-“cured”-variant was checked using the OrthoMCL
pipeline [19]. In a second approach the phylogenetic
distances of all strains were tested. The set of genes,
which is present in each of all strains, the Maximum
Common Genome (MCG), was therefore calculated,
the allelic variants of the MCG from the strains was
then extracted and a multiple alignment was built
(Semmler, personal communication). Verified ESBL-
plasmid-free strains were henceforward named PCV
(plasmid-“cured” variant: PCV977549, PCV19205,
PCV27685, PCV16316, PCV964041.2, PCV21183 and
PCV23463). Presence of genes for TA systems on plasmidsFigure 2 Electropherogram of the plasmid-profile-analysis. Wild-type (
in pairs. Revolved in white are the big plasmids in the ESBL-wild-type strain
beginning and the end are several markers (1 kb plus [Thermo Scientific, U
[36.8/4.8/3.7/2.0/1.8/1.4], FastRuler High range DNA [ThermoScientific USA])was investigated evaluating sequence data using bioinfor-
matic methods. Both wild-type strains as well as PCVs
were sequenced by an Illumina HiSeq 2000 sequencer. The
resulting reads for the PCVs were used for a de novo assem-
bly (CLC Genomics Workbench 6.5, CLC Bio, Denmark).
The contigs were then used as reference sequences for a
reference mapping of the reads from the wild-type strains.
All reads from the wild-type strains, which could not be
mapped to the PCV sequence are supposed to represent
the extracted plasmids and were used for another de novo
assembly, which resulted in the contigs of the plasmid
sequences. Using BLAST for the plasmid and the PCV
contigs, the genes for TA systems could be localized.
Other plasmid-“curing” methods including treatment
of bacteria with acridine orange and ethidium bromide
[14] were additionally tested and modified, however, as
they turned out not to be successful, data are not included
in this manuscript.
Results
Treatment of bacteria with enhanced temperatures was per-
formed to construct viable toxin-antitoxin system-containing
ESBL-plasmid-“cured”-variants of wild-type ESBL-E.
coli strains. Following three to six weeks of daily
sub-cultivation, examination of the phenotypical re-
sistance status of the wild-type ESBL-strains revealed
seven cefotaxime-susceptible and phenotypically ESBL-
plasmid-“cured”-variants. Table 2 shows the results of
agar disc diffusion testing of cefotaxime and other classes
of antimicrobials. All PCVs lost their cefotaxime resistance
along with most of the non-beta lactam resistances. ClonalIMT/VB, left) and ESBL-plasmid-“cured” variants (PCVs, right) illustrated
s, which have been “cured” in the corresponding PCVs. At the
SA], X-109/97 [12,5MDa], STm [60MDa], R478 [166MDa], V517
.
Schaufler et al. Gut Pathogens 2013, 5:34 Page 5 of 6
http://www.gutpathogens.com/content/5/1/34identity of the PCV and its wild-type strain was proven via
pulsed-field gel electrophoresis (Figure 1) and bioinfor-
matic analyses. The seven PCV strains showed a highly
similar macrorestriction pattern compared to their corre-
sponding wild-type strain. For most of the PCV strains, a
small band was missing in the patterns, which might
be the “cured” plasmid itself (PCV977549, PCV16316,
PCV964041.2 and PCV21183). Comparing orthologous
genes, similar results were obtained for all pairs, which
showed only one significant excess of genes in the wild-
type strain without an ortholog in the “cured”-variant in
an amount that corresponds to the size of the plasmid. In
case of phylogenetic distances a clustering confirmed the
genetic identity for each pair of wild-type and plasmid-
“cured”-variant strain (data not shown). The loss of large
plasmids (>100 kb) was approved via plasmid-profile-
analysis (Figure 2). Plasmid-profile analysis revealed no
loss of other smaller plasmids apart from the large ESBL-
resistance plasmids. Bioinformatic analyses confirmed the
presence of different TA system-genes on plasmids in-
cluding hok/sok, srnB/C, vagC/D, pemI/K. All but
one wild-type strain (IMT19205) carried ESBL-plasmids
encoding for multiple TA systems, whereat all plasmids
belonged either to replicon types FIA or FIB (Table 1).
Conclusions and discussion
As ESBL-plasmid-“curing” of the strains applied in this
study did not work treating bacteria with ethidium brom-
ide or acridine orange a previously described method [15]
using a heat technique was performed. This method was
adequate to construct viable PCVs and to our knowledge
we are the first ones to describe a successful “curing”
of ESBL-plasmids, which carry genes for toxin-antitoxin
systems. The results are surprising because one might
think that bacteria cannot survive without this plasmid.
Strains used in this study all had at least one complete
ESBL-plasmid-encoded toxin-antitoxin system, includ-
ing hok/sok, srnB/C, vagC/D and pemI/K, which were
encoded on plasmids of replicon types FIA or FIB carrying
blaCTX-M-9, blaCTX-M-14 and blaCTX-M-15 or combinations
of these three ESBL-genes. The addiction systems and
replicon types found have been characterized in ESBL-
producing E. coli before and certain combinations of
ESBL-enzyme, addiction systems and replicon type might
contribute to the success and spread of multi-resistant
E. coli strains [13]. An association of CTX-M-15 with FIA
and CTX-M-9 with FIB plasmids has been described before
and the same was true for the isolates used in this study
(Table 1). Mnif et al. also observed that the occurrence
of CTX-M-14 correlated with FII replicons, however,
FIB replicon type plasmids carrying CTX-M-14 have
also been found in this earlier study [13]. No correlation
for CTX-M-14 and FII replicons was observed in this
study, as this ESBL-type was also present on FIA/FIBplasmids (Table 1). This might be partly due to the fact
that blaCTX-M-14 was only detected in combination with
other CTX-M enzymes (Table 1). So why did bacteria,
whose TA system-containing plasmid was “cured” using
a heat technique, survive? One might speculate that
some toxins degenerate irreversibly above certain temper-
atures or that the TA genes are not expressed at 45°C.
Or is it that continuing soft stimulation using high
temperatures allows a slow adaption to changing environ-
mental conditions and therefore “curing” of the plasmid,
while chemicals, like ethidium bromide, together with the
loss of a TA system mean too much stress for bacteria?
Pulsed-field gel electrophoresis, plasmid-profile-analysis
and bioinformatic analyses confirmed that the genetic
change is restricted solely to the loss of an ESBL-plasmid
and that genetic identity of PCV and wild-type strain re-
mains given. Constructed PCV strains might be important
tools to investigate the influence of an ESBL-plasmid on
its bacterial host.
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